ECOG randomized patients with advanced NSCLC to 1 of 4 new 3 of the 4 regimens used in ECOG docetaxel/cisplatin, paclitaxel/cisplatin. In the ECOG trial, the only direct comparison of similar regimens, response rates and survival times were similar between patients treated with cisplatin. ECOG was chosen as a plenary session presentation because it is an important trial that reflects the state of care in of metastatic NSCLC—the.
|Published (Last):||15 December 2008|
|PDF File Size:||18.1 Mb|
|ePub File Size:||7.2 Mb|
|Price:||Free* [*Free Regsitration Required]|
Lung Cancer ; Disclosure — in the Blink of an Eye. Lung Cancer Highlights Thomas J.
Six patients treated with chemotherapy plus antibody had life-threatening hemoptysis and four died. Prognostic factors for patients with advanced non-small cell lung cancer: Do all patients ecov advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review
Patient characteristics were reflective of the standard population of patients in advanced lung cancer trials.
User Name Password Sign In. Patients were stratified by performance status, weight loss, stage and presence of brain metastases. The relative dose intensities were 0. These findings eclg not be ignored, especially considering the availability of several drugs characterised by a favourable toxicity profile.
Lung cancer in Europe in European Organization for Research and Treatment of Cancer First, the current study allowed patients with brain metastases to participate.
Ultimately new drugs against new targets are the future of lung cancer therapy. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. QOL was categorized as improved, stable, or declined. This decision was made because of a high rate of serious adverse events in patients with PS scores of 2. However, the poor outcome in the PS-2 patients resulted in restricting the eligibility to those with PS-0, 1.
Nevertheless, PS2 patients had significant benefit from chemotherapy and, with the greater potential for palliation determined by worse baseline condition, showed an improvement in QoL even higher than PS0 and PS1 patients. A review of these studies is useful in assessing if the pharmacokinetic and pharmacologic differences between these agents are reflected in the efficacy, adverse-event profile, and QOL benefits of the taxanes in patients with advanced NSCLC.
The response rate and survival did not differ significantly between patients assigned to receive cisplatin and paclitaxel and those assigned to receive any of the three experimental regimens. Docetaxel Taxotere shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: Treatment with cisplatin and gemcitabine was associated with a significantly longer time to the progression of disease than was treatment with cisplatin and paclitaxel but was more likely to cause grade 3, 4, or 5 renal toxicity in 9 percent of patients, vs.
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
The ecoh part of the evidence analysed in the meeting comes from small sub-groups of patients with PS2, enrolled in clinical trials usually including patients with a PS ranging from 0 to 2.
In a series of more than patients with inoperable lung cancer analysed more than two decades ago to investigate the impact on survival of 50 prognostic factors, performance status, extent of disease and weight loss were among the most important prognostic factors [ efog ].
Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small-cell lung cancer: The deaths were all in patients with squamous cell cancer. From the Cover Conflict of Interest: Study Design and Results The study by Noda et al. Survival determinants in extensive-stage non-small-cell lung cancer: The outcome of 64 PS2 patients enrolled in the clinical trial ECOG comparing four platinum-based combinations has been analysed in detail, after the accrual of PS2 patients had been stopped because of the perception of an excessive number of adverse events in this sub-group [ 27 ].
Several features of target-based molecules make these drugs potentially ideal treatments for unfit patients. N Engl J Med. There were no statistically significant between-group differences in QOL at either 13 or 25 weeks.